# COVID-19 (mild, outpatient) - Category: infectious - Review status: reviewed (every claim checked against a document named on this page) - Sources: Lagevrio 200 mg hard capsules SmPC sections 4.2 and 4.4 (eMC product 13044) · NICE Guideline NG191: Managing COVID-19 2023 · NIH COVID-19 Treatment Guidelines 2023 · WHO Therapeutics and COVID-19: Living Guideline 2023 - Verified date: 2026-08 ## Verified against - Lagevrio 200 mg hard capsules SmPC sections 4.2 and 4.4 (eMC product 13044) - NIH COVID-19 Treatment Guidelines 2023 - WHO Therapeutics and COVID-19: Living Guideline 2023 - COVID-19 (mild, outpatient) - disease-level clinical article (covid-19-outpatient-clinical.txt) - MSF Essential Drugs 2024 - paracetamol (oral) for the antipyretic figures: "Adult: 1 g 3 or 4 times daily (max. 4 g daily)" and "Child 1 month and over: 15 mg/kg 3 or 4 times daily (max. 60 mg/kg daily)". The hydration, rest and saturation monitoring are supportive measures from the WHO Therapeutics and COVID-19: Living Guideline 2023, which is not held in this corpus. ## Treatment metadata - Supportive Care and Symptom Management - Referral & safety-netting (no drug therapy) - Nirmatrelvir / Ritonavir — 300 mg — oral.solid - Molnupiravir — 200 mg — oral.solid ## Complete treatment card ```text COVID-19 (MILD, OUTPATIENT) Sources: Lagevrio 200 mg hard capsules SmPC sections 4.2 and 4.4 (eMC product 13044) · NICE Guideline NG191: Managing COVID-19 2023 · NIH COVID-19 Treatment Guidelines 2023 · WHO Therapeutics and COVID-19: Living Guideline 2023 Review status: REVIEWED against Lagevrio 200 mg hard capsules SmPC sections 4.2 and 4.4 (eMC product 13044), NIH COVID-19 Treatment Guidelines 2023, WHO Therapeutics and COVID-19: Living Guideline 2023, COVID-19 (mild, outpatient) - disease-level clinical article (covid-19-outpatient-clinical.txt), MSF Essential Drugs 2024 - paracetamol (oral) for the antipyretic figures: "Adult: 1 g 3 or 4 times daily (max. 4 g daily)" and "Child 1 month and over: 15 mg/kg 3 or 4 times daily (max. 60 mg/kg daily)". The hydration, rest and saturation monitoring are supportive measures from the WHO Therapeutics and COVID-19: Living Guideline 2023, which is not held in this corpus. (2026-08) IS IT THIS? - reference only, to read alongside your own examination SYMPTOMS - what the patient reports (4) - Most symptomatic patients report fever, cough, and shortness of breath [breathlessness · cough · fever] - Sore throat, loss of smell or taste, malaise, myalgia, and diarrhea are less common symptoms [diarrhoea · loss of smell · malaise · muscle pain · sore throat] - About 17.9% to 33.3% of those infected have no symptoms at all - Mild illness has typical COVID symptoms but no breathlessness and normal chest imaging SIGNS - what you find (3) - Moderate illness features lower respiratory disease with oxygen saturation of 94% or higher on room air - Severe illness shows SpO2 below 94%, a respiratory rate over 30 per minute, or lung infiltrates over 50% of lung volume - Pseudo-chilblain-like acral lesions are the most common skin finding, seen in about 40% of cases TESTS (6) - Nasopharyngeal PCR for SARS-CoV-2 RNA is the standard diagnostic test - Antigen tests are faster but less sensitive than PCR - Serologic (antibody) testing is not recommended to diagnose acute infection - D-dimer level helps choose between therapeutic and prophylactic anticoagulation dosing - Chest x-ray is normal in about one in five patients despite confirmed infection - Routine chest CT is not advised for screening or diagnosing COVID-19 IF NOT THIS - what else fits (5) - Community-acquired bacterial pneumonia is on the differential list - Influenza infection is a key differential given the overlapping symptoms - Aspiration pneumonia is on the differential list - Pneumocystis jirovecii pneumonia is a differential, notably in immunocompromised patients - Pulmonary tuberculosis is on the differential list Source StatPearls "Features, Evaluation, and Treatment of Coronavirus (COVID-19)" - disease-level clinical article Status traced to the source above 1. SUPPORTIVE CARE AND SYMPTOM MANAGEMENT [1st line] Adult Symptomatic relief with an antipyretic (paracetamol 1 g 3 or 4 times daily, max. 4 g daily), adequate hydration, rest, and monitoring oxygen saturation (SpO2) x 5-10 days Peds Paracetamol, child 1 month and over: 15 mg/kg 3 or 4 times daily (max. 60 mg/kg daily). Child under 1 month: 10 mg/kg 3 or 4 times daily (max. 40 mg/kg daily). Ensure adequate hydration and monitor for red flag signs (respiratory distress, lethargy). Source MSF Essential Drugs 2024 - paracetamol (oral) for the antipyretic figures: "Adult: 1 g 3 or 4 times daily (max. 4 g daily)" and "Child 1 month and over: 15 mg/kg 3 or 4 times daily (max. 60 mg/kg daily)". The hydration, rest and saturation monitoring are supportive measures from the WHO Therapeutics and COVID-19: Living Guideline 2023, which is not held in this corpus. Why For mild COVID-19 in low-risk outpatient individuals without risk factors for severe disease, specific antiviral therapy is not indicated; supportive care is standard Caution Refer urgently to hospital if SpO2 falls below 94% on room air, or if patient develops severe dyspnoea, confusion, or persistent chest tightness. Routine antibiotics, systemic corticosteroids, or hydroxychloroquine are NOT recommended for mild outpatient COVID-19 without bacterial coinfection. 2. REFERRAL & SAFETY-NETTING (NO DRUG THERAPY) [1st line] Adult Source COVID-19 (mild, outpatient) - disease-level clinical article (covid-19-outpatient- clinical.txt) Why Carries the referral criteria and warning signs for this condition, which apply whichever treatment is chosen. Caution RED FLAG - Monitor for sudden clinical deterioration leading to acute respiratory failure or ARDS. 3. NIRMATRELVIR / RITONAVIR [2nd line] Adult Nirmatrelvir 300 mg (two 150 mg tablets) plus Ritonavir 100 mg (one 100 mg tablet) taken together twice daily (start within 5 days of symptom onset) x 5 days Peds 12 years and over: 300 mg / 100 mg twice daily for 5 days (as for adults), for adolescents weighing at least 40 kg. (Approved for adolescents >=12 years weighing at least 40 kg at adult dose (300 mg / 100 mg BID for 5 days). Not recommended in children <12 years.) Source NIH COVID-19 Treatment Guidelines 2023 Why For high-risk outpatients within 5 days of symptoms. Paxlovid has little retail presence in Egypt - see molnupiravir below for what is actually on the shelf. Caution Severe drug interaction potential due to CYP3A inhibition by ritonavir; perform comprehensive medication reconciliation before prescribing. Contraindicated in severe renal impairment (eGFR <30 mL/min) and severe hepatic impairment (Child-Pugh Class C). Requires dose adjustment in moderate renal impairment (eGFR 30-59 mL/min: Nirmatrelvir 150 mg + Ritonavir 100 mg BID). Egypt no Egyptian brand matched - prescribe by generic name 4. MOLNUPIRAVIR [2nd line] Adult 800 mg - four 200 mg capsules - every 12 hours for 5 days, started within 5 days of symptom onset x 5 days exactly Peds Not for use under 18 years - no safety or efficacy data. Choice Availability decides. Nirmatrelvir/ritonavir has no Egyptian product in the register; molnupiravir has 8. Source Lagevrio 200 mg hard capsules SmPC sections 4.2 and 4.4 (eMC product 13044) Why The antiviral that is actually registered and stocked in Egypt: eight products, 318-624 EGP for the whole 40-capsule course. Read the cautions before reaching for it - the evidence is weaker than the price suggests. Caution PANORAMIC, the large trial in vaccinated high-risk adults in the community, found no reduction in hospital admission or death. WHO's recommendation is conditional and confined to those at highest risk. In a vaccinated patient this is 300-600 EGP for a benefit that has not been shown. Not recommended in pregnancy - animal reproductive toxicity. A woman who could become pregnant needs effective contraception during the course and for 4 days after the last dose. Exactly 5 days. Longer has not been studied and there is no reason to extend it. No dose change needed for renal or hepatic impairment. Egypt MOLNUVOC 200 MG 40 CAPS. AMOUN 318.00 EGP (7.95/unit) MOLNUPRAVA 200 MG 40 CAPS. EUROPEAN EGYP... 420.00 EGP (10.50/unit) PIROLOGLOB 200 MG 40 CAPS. GLOBAL ADVANC... 420.00 EGP (10.50/unit) COVAPRAVIR 200 MG 40 CAPS. EIPICO 461.00 EGP (11.53/unit) MOLNUPIRAVIR-EVA 200 MG 40 CAPS. EVA PHARMA 461.00 EGP (11.53/unit) MOLNUPIRAVIR-RAMEDA 200 MG 40 CAPS. RAMEDA 461.00 EGP (11.53/unit) AUGIPRIVIR 200 MG 40 CAPS. AUG PHARMA 624.00 EGP (15.60/unit) HOCHSTERPRIVER 200 MG 40 CAPS. HOCHSTER PHAR... 624.00 EGP (15.60/unit) Prices are indicative (dataset snapshot 2026-06); verify with the pharmacy. ``` --- Dawaa Reference is a reference for prescribers, not a medical device, and does not replace clinical judgement. [Privacy policy](/privacy)